CROI 2016 Program at a Glance

Program and Agenda

761 Neurocognitive Function in HIV-Infected Persons With Cryptococcal Antigenemia Martha P. Montgomery 1 ; Noeline Nakasujja 2 ; Bozena M. Morawski 1 ; Radha Rajasingham 1 ; Elizabeth Nalintya 3 ; Renee Donahue Carlson 4 ; Jona E. Kaplan 5 ; Andrew Kambugu 3 ; David B. Meya 3 ; David R. Boulware 1 ; for the COAT and ORCASTrialTeams 1 UnivofMinnesota,Minneapolis,MN,USA; 2 MakerereUnivCollofHlth Scis,Kampala,Uganda; 3 InfectiousDiseases Inst,Kampala,Uganda; 4 EmoryUnivSchofMed,Atlanta,GA,USA; 5 CDC,Atlanta,GA,USA 1:45 PM-2:45 PM New Drugs for Kids: What's Taking so Long? Themed Discussion Leader Martina Penazzato ,WorldHealthOrganization,Geneva,Switzerland 815 Nevirapine (NVP) Concentrations in HIV-Infected Newborns Receiving Therapeutic Dosing 1 UnivofCaliforniaSanDiego,SanDiego,CA,USA; 2 BotswanaHarvard AIDS InstPartnership,Gaborone,Botswana; 3 HenryM. JacksonFndn for theAdvancementofMilitaryMed, Inc,Rockville,MD,USA; 4 Harvard SchofPH,Boston,MA,USA; 5 Ragon InstofMGH,MITandHarvard, Cambridge,MA,USA; 6 HarvardMedSch,Boston,MA,USA 816 IMPAACT 1093: Dolutegravir in 6- to 12-Year-Old HIV-Infected Children: 48-Week Results Edmund Capparelli 1 ; Kenneth Maswabi 2 ; Steven Rossi 1 ; Muchaneta Bhondai 2 ; Sikhulile Moyo 2 ; Patrick Jean-Philippe 3 ; Michael Hughes 4 ; Mathias Lichterfeld 5 ; Daniel Kuritzkes 6 ; Roger L. Shapiro 4 AndrewWiznia 1 ; Carmelita Alvero 2 ;Terry Fenton 3 ; Kathleen George 4 ; EllenTownley 5 ; Rohan Hazra 6 ; Bobbie Graham 7 ; Annie Buchanan 8 ; CindyVavro 9 ; RolandoViani 10 ; for the IMPAACT P1093 1 AlbertEinsteinCollofMed,Bronx,NY,USA; 2 HarvardSchofPH,Boston, MA,USA; 3 SDAC,HarvardSchofPH,Boston,MA,USA; 4 IMPAACT Operations,Durham,NC,USA; 5 NIH,Rockville,MD,USA; 6 EuniceKennedy ShriverNICHD,Bethesda,MD,USA; 7 FrontierSci&TechRsrFndn, Inc, Buffalo,NY,USA; 8 GSK,ResearchTrianglePark,NC,USA; 9 ViiVHlthcare, ResearchTrianglePark,NC,USA; 10 UnivofCaliforniaSanDiego,San Diego,CA,USA 817 Safety and Efficacy of E/C/F/TAF in HIV-1 Infected Treatment-Naïve Adolescents 1 St JudeChildren’sRsrHosp,Memphis,TN,USA; 2 JointClinicalRsrCntr, Kampala,Uganda; 3 EmoryUniv,Atlanta,GA,USA; 4 MillerChildren’sHosp, LongBeach,CA,USA; 5 KhonKaenUniv,KhonKaen,Thailand; 6 Queen SavangVadhanaMemorialHosp,ChonBuri,Thailand; 7 GileadScis, Inc, FosterCity,CA,USA 1120 Pharmacokinetics, Safety, and Efficacy of Maraviroc in Pediatric Patients With R5 HIV Carlo Giaquinto 1 ; Muthuhadini P. Mawela 2 ; Kulkanya Chokephaibulkit 3 ; Annie Fang 4 ; Elna van der Ryst 5 ; Srinivas RaoValluri 4 ; ManoliVourvahis 4 ; Rebecca Zhang-Roper 6 ; Lynn McFadyen 7 ; Jayvant Heera 8 1 UnivofPadova,Padova, Italy; 2 SefakoMakgathoHlthScisUniv,Pretoria, SouthAfrica; 3 SirirajHosp,MahidolUniv,Bangkok,Thailand; 4 Pfizer, Inc, NewYork,NY,USA; 5 Pfizer Inc,TheRsrNetwork,Sandwich,UK; 6 GSK, StockleyPark,UK; 7 Pfizer, Inc,Sandwich,UK; 8 Pfizer, Inc,Groton,CT,USA Aditya Gaur 1 ; Hilda Kizito 2 ; Rana Chakraborty 3 ; Jagmohan Batra 4 ; Pope Kosalaraksa 5 ;Wicharn Luesomboon 6 ;Yongwu Shao 7 ; Devi SenGupta 7 ; Martin S. Rhee 7 ; Erin Quirk 7 Session TD-10 Themed Discussion Room 311

819 Safety of Tenofovir on Bone Mineral Density in HIV-Infected Youths: A 10-Year Study Vania Giacomet 1 ; Katia Maruca 2 ; Paola Erba 1 ; Maria Puzzovio 2 ; Pilar Nannini 3 ; Silvia Capelli 2 ; Alessandro Ambrosi 2 ; Gianvincenzo Zuccotti 4 ; Stefano Mora 2 1 LuigiSaccoHosp,UnivofMilan,Milan, Italy; 2 SanRaffaeleScientific Inst,Milan, Italy; 3 UnivofMilan,Milan, Italy; 4 OspedaleBuzzi,Univof Milan,Milan, Italy 1:45 PM-2:45 PM Innovations to Enhance Treatment Outcomes Themed Discussion Leader Moses R. Kamya ,MakerereUniversityCollegeofHealthSciences, Kampala,Uganda 1011 The Real-World Impact of CD4-Eligibility Criteria on Retention in HIV Care Jacob Bor 1 ; Matthew P. Fox 2 ; Sydney Rosen 2 ; Atheendar Venkataramani 3 ; FrankTanser 4 ; Deenan Pillay 4 ;Till Bärnighausen 5 1 BostonUnivSchofPH,Boston,MA,USA; 2 BostonUniv,Boston,MA, USA; 3 MassachusettsGeneralHosp,Boston,MA,USA; 4 AfricaCntr for HlthandPopStudies,Mtubatuba,SouthAfrica; 5 HarvardSchofPH, Boston,MA,USA 1012 Do ART Eligibility Expansions Crowd out the Sickest? Evidence From South Africa Sheryl A. Kluberg 1 ; Matthew P. Fox 2 ; Michael LaValley 1 ;Till Bärnighausen 3 ; Deenan Pillay 4 ; Jacob Bor 1 1 BostonUnivSchofPH,Boston,MA,USA; 2 BostonUniv,Boston,MA, USA; 3 HarvardSchofPH,Boston,MA,USA; 4 AfricaCntr forHlthandPop Studies,Mtubatuba,SouthAfrica 1018 Evaluating Appointment Patterns to Improve Sustainability of HIV Treatment in Zambia Monika Roy 1 ; Charles Holmes 2 ; Izukanji Sikazwe 2 ;Thea Savory 2 ; Mwanza Mwanza 2 ; Carolyn Moore 2 ; Kafula Mulenga 2 ; Nancy L. Czaicki 3 ; Nancy Padian 3 ; Elvin H. Geng 1 1 UnivofCaliforniaSanFrancisco,SanFrancisco,CA,USA; 2 Cntr for InfectiousDiseaseRsr inZambia,Lusaka,Zambia; 3 UnivofCalifornia Berkeley,Berkeley,CA,USA 1031 Outcomes of Patients Enrolled in ART Adherence Clubs After Viral Resuppression JosephT. Sharp 1 ; LynneWilkinson 2 ;Vivian Cox 2 ; Carol Cragg 3 ; Gilles Van Cutsem 4 ; Anna Grimsrud 5 1 UnivofCapeTown,CapeTown,SouthAfrica; 2 MédecinsSansFrontières, Khayelitsha,SouthAfrica; 3 WesternCapeDeptofHlth,CapeTown,South Africa; 4 MédecinsSansFrontières,CapeTown,SouthAfrica; 5 IAS,Cape Town,SouthAfrica 1016 Barriers to Care and 1-Year Mortality in Newly Diagnosed HIV+ Persons in South Africa IngridV. Bassett 1 ; Sharon M. Coleman 2 ; Janet Giddy 3 ; Laura M. Bogart 4 ; Christine E. Chaisson 2 ; Douglas Ross 5 ;Tessa Govender 3 ; Rochelle P.Walensky 1 ; Kenneth A. Freedberg 1 ; Elena Losina 6 1 MassachusettsGeneralHosp,Boston,MA,USA; 2 BostonUnivSchof PH,Boston,MA,USA; 3 McCordHosp,Durban,SouthAfrica; 4 Boston Children’sHosp,HarvardMedSch,Boston,MA,USA; 5 MidlandsMedCntr, Pietermaritzburg,SouthAfrica; 6 BrighamandWomen’sHosp,Harvard MedSch,Boston,MA,USA Session TD-11 Themed Discussion Ballroom A

Wednesday, February 24, 2016 • Oral Sessions

39

CROI 2016